Key result
High dose polyoestradiol phosphate (160 mg) was not associated with increased cardiovascular risk, with 0% cardiovascular mortality and thromboembolic complications in all treatment groups.
Why the study?
Does high dose polyoestradiol phosphate with or without acetosalicylic acid compared to orchiectomy affect clinical efficacy and cardiovascular complications in prostatic cancer patients?
RCT (n=200)
randomised
Yes
Does high dose polyoestradiol phosphate with or without acetosalicylic acid compared to orchiectomy affect clinical efficacy and cardiovascular complications in prostatic cancer patients?
Absolute Event Rate: 0% vs 0%
Parenteral high dose polyoestradiol phosphate is not associated with an increased risk of cardiovascular complications in the first 6 months, and there is no need for daily low dose acetosalicylic acid.
Supports omitting routine antiplatelet therapy with high-dose parenteral estrogen in prostate cancer; extends RCT evidence on short-term cardiovascular safety.
The clinical efficacy of high dose (160 mg) polyoestradiol phosphate (PEP) was compared with that of orchiectomy in a prospective randomised multicentre study including 200 prostatic cancer patients. The effect of daily low dose (75 mg) acetosalicylic acid (ASA) on possible cardiovascular complications during the first 6 months of therapy was also evaluated. Oestrogen-treated patients had more progressions, but follow-up was too short to draw any definite conclusions on the efficacy of treatment. There was no cardiovascular mortality and there were no thromboembolic complications in any treatment group. It was concluded that parenteral high dose PEP is not associated with an increased risk of cardiovascular complications and there is no need for daily low dose ASA.
No takes yet. Share an insight, caveat, or question.
Aro et al. (1989) conducted an RCT in prostatic cancer (n=200). Polyoestradiol phosphate (PEP) with or without acetosalicylic acid (ASA) vs. Orchiectomy was evaluated on Cardiovascular mortality and thromboembolic complications. High dose polyoestradiol phosphate (160 mg) was not associated with increased cardiovascular risk, with 0% cardiovascular mortality and thromboembolic complications in all treatment groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: